BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18060745)

  • 1. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors.
    Ozgunes I; Erben N; Kiremitci A; Kartal ED; Durmaz G; Colak H; Usluer G; Colak E
    Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
    Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integron-mediated ESBL resistance in rare serotypes of Escherichia coli causing infections in an elderly population of Israel.
    Sompolinsky D; Nitzan Y; Tetry S; Wolk M; Vulikh I; Kerrn MB; Sandvang D; Hershkovits G; Katcoff DJ
    J Antimicrob Chemother; 2005 Jan; 55(1):119-22. PubMed ID: 15574469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
    Bell JM; Chitsaz M; Turnidge JD; Barton M; Walters LJ; Jones RN
    J Clin Microbiol; 2007 May; 45(5):1478-82. PubMed ID: 17344367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
    Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women.
    Ho PL; Poon WW; Loke SL; Leung MS; Chow KH; Wong RC; Yip KS; Lai EL; Tsang KW;
    J Antimicrob Chemother; 2007 Jul; 60(1):140-4. PubMed ID: 17496058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp].
    Ekşi F; Ozer G; Balci I
    Mikrobiyol Bul; 2007 Jul; 41(3):447-52. PubMed ID: 17933257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London.
    Skippen I; Shemko M; Turton J; Kaufmann ME; Palmer C; Shetty N
    J Hosp Infect; 2006 Oct; 64(2):115-23. PubMed ID: 16859810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incidence of infections dues to Escherichia coli strains producing extended spectrum betalactamase, in the Zou/Collines Hospital Centre (CHDZ/C) in Benin].
    Ahoyo AT; Baba-Moussa L; Anago AE; Avogbe P; Missihoun TD; Loko F; Prévost G; Sanni A; Dramane K
    Med Mal Infect; 2007 Nov; 37(11):746-52. PubMed ID: 17434702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.
    Colodner R; Samra Z; Keller N; Sprecher H; Block C; Peled N; Lazarovitch T; Bardenstein R; Schwartz-Harari O; Carmeli Y;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):201-5. PubMed ID: 17258084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C
    Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
    Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
    Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases.
    Lavigne JP; Blanc-Potard AB; Bourg G; Moreau J; Chanal C; Bouziges N; O'callaghan D; Sotto A
    Clin Microbiol Infect; 2006 Dec; 12(12):1199-206. PubMed ID: 17121626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.